News
Max Delbrück Center signs licence agreement with Kite, a Gilead Company, for Sleeping Beauty Transposon System
20.11.2024 / Supported by its technology transfer partner Ascenion, Max Delbrück Center has entered into a licensing agreement with Kite providing the company with non-exclusive rights to use the transposon system for the genetic engineering of T cells.
The Sleeping-Beauty Transposase System, consisting of a transposase and a transposon, enables cost-effective, simple and highly efficient gene transfer. It offers an attractive alternative to viral gene transfer systems, because it significantly reduces the risks of immunogenicity or insertional mutagenesis and facilitates GMP compliance. Several therapies including CAR T-cell approaches using the Sleeping Beauty System are already in clinical testing.
Kite, a global biopharmaceutical company focused on cell therapy to achieve cures, will employ the technology for the genetic engineering of T cells. As the global cell therapy leader, it has treated more patients with CAR T-cell therapy than any other company.
The licensed Sleeping Beauty technology was developed at the Max Delbrück Center by Dr Zsuzsanna Izsvák and Prof. Dr Zoltán Ivics (currently at Fraunhofer Institute for Cell Therapy and Immunology IZI). With Ascenion’s help, it has already been licensed for a number of different applications, including cell and gene therapy, bioproduction and as an R&D tool.
Further information on the technology
Source: Ascenion GmbHNews in brief from Ascenion
